Clinical Trial Update: Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing lenvatinib plus a PD-1 antibody versus lenvatinib alone for hepatocellular carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: WITHDRAWN